146 related articles for article (PubMed ID: 36140275)
1. Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma.
Tompa M; Kraboth Z; Galik B; Kajtar B; Gyenesei A; Kalman B
Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140275
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation and protein expression of Wnt pathway markers in progressive glioblastoma.
Tompa M; Kajtar B; Galik B; Gyenesei A; Kalman B
Pathol Res Pract; 2021 Jun; 222():153429. PubMed ID: 33857857
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the Catecholamine Pathway in Glioblastoma Development.
Kraboth Z; Kajtár B; Gálik B; Gyenesei A; Miseta A; Kalman B
Cells; 2021 Mar; 10(3):. PubMed ID: 33806345
[TBL] [Abstract][Full Text] [Related]
4. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
[TBL] [Abstract][Full Text] [Related]
5. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.
Martinez R; Setien F; Voelter C; Casado S; Quesada MP; Schackert G; Esteller M
Carcinogenesis; 2007 Jun; 28(6):1264-8. PubMed ID: 17272309
[TBL] [Abstract][Full Text] [Related]
6. SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients.
Feng Y; Wang Z; Bao Z; Yan W; You G; Wang Y; Hu H; Zhang W; Zhang Q; Jiang T
PLoS One; 2014; 9(3):e91829. PubMed ID: 24633048
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma epigenomics discloses a complex biology and potential therapeutic targets.
Krabóth Z; Tompa M; Urbán P; Gálik B; Kajtár B; Gyenesei A; Kálmán B
Ideggyogy Sz; 2024 Jan; 77(1-2):27-37. PubMed ID: 38321856
[TBL] [Abstract][Full Text] [Related]
8. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.
Yu Z; Yang H; Song K; Fu P; Shen J; Xu M; Xu H
Front Oncol; 2022; 12():938679. PubMed ID: 35982954
[TBL] [Abstract][Full Text] [Related]
9. DNA CpG methylation in sequential glioblastoma specimens.
Kraboth Z; Galik B; Tompa M; Kajtar B; Urban P; Gyenesei A; Miseta A; Kalman B
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2885-2896. PubMed ID: 32779022
[TBL] [Abstract][Full Text] [Related]
10. DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis.
Foltz G; Yoon JG; Lee H; Ryken TC; Sibenaller Z; Ehrich M; Hood L; Madan A
Oncogene; 2009 Jul; 28(29):2667-77. PubMed ID: 19465937
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide methylation analyses in glioblastoma multiforme.
Lai RK; Chen Y; Guan X; Nousome D; Sharma C; Canoll P; Bruce J; Sloan AE; Cortes E; Vonsattel JP; Su T; Delgado-Cruzata L; Gurvich I; Santella RM; Ostrom Q; Lee A; Gregersen P; Barnholtz-Sloan J
PLoS One; 2014; 9(2):e89376. PubMed ID: 24586730
[TBL] [Abstract][Full Text] [Related]
14. Homeobox genes gain trimethylation of histone H3 lysine 4 in glioblastoma tissue.
Luo K; Luo D; Wen H
Biosci Rep; 2016 Jul; 36(3):. PubMed ID: 27160082
[TBL] [Abstract][Full Text] [Related]
15. The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma.
Cecener G; Tunca B; Egeli U; Bekar A; Tezcan G; Erturk E; Bayram N; Tolunay S
Cell Mol Neurobiol; 2012 Mar; 32(2):237-44. PubMed ID: 21928112
[TBL] [Abstract][Full Text] [Related]
16. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome.
Bai Y; Zhang QG; Wang XH
Eur J Med Res; 2014 Dec; 19(1):66. PubMed ID: 25498217
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
19. Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience.
Baur M; Preusser M; Piribauer M; Elandt K; Hassler M; Hudec M; Dittrich C; Marosi C
Radiol Oncol; 2010 Jun; 44(2):113-20. PubMed ID: 22933901
[TBL] [Abstract][Full Text] [Related]
20. Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade Glioma.
Peshes-Yeloz N; Ungar L; Wohl A; Jacoby E; Fisher T; Leitner M; Nass D; Rubinek T; Wolf I; Cohen ZR
World Neurosurg; 2019 Oct; 130():e324-e332. PubMed ID: 31228703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
